Results 51 to 60 of about 1,670 (156)
Oceanography and Pacific Oyster Biochemical Composition in a Novel Oyster‐Growing Region
Aquaculture, Fish and Fisheries, Volume 5, Issue 5, October 2025.ABSTRACT The farming of Pacific oysters (Crassostrea [Magallana] gigas) is a rapidly growing industry in Alaska, where farms represent some of the highest latitude oyster cultivation efforts in the world. Little is known about the nearshore oceanography where Alaskan farms are located, or how the subarctic marine context influences oyster tissue ...
Rebecca Cates +8 more
wiley +1 more source
Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring
Orphanet Journal of Rare Diseases, 2009 Background In Fabry disease (α-galactosidase A deficiency) accumulation of Globotriaosylceramide (Gb3) leads to progressive organ failure and premature death.
Hoffmann Björn
doaj +1 more source
The Role of Genetics in Stroke Risk and Outcome: A Review of Current Evidence
Brain and Behavior, Volume 15, Issue 10, October 2025.This study delineates the multiple pathways leading to stroke, encompassing genetic risk factors such as lipid/cholesterol metabolism, blood pressure regulation genes, and endothelial dysfunction. The report includes genetic pathways such as Val66Met polymorphism, prothrombin G20210A, interleukin‐6 and tumor necrosis factor gene variant, along with ...
Mega Obukohwo Oyovwi +3 more
wiley +1 more source
Indian Journal of Dermatology, 2001 A case of Anderson â€" Fabryâ€s disease presenting with cutaneous, ophthalmic and cardiological manifestations leading to death at an uncharacteristically early age is reported.
Coondoo Arijit +2 more
doaj
Gene Therapy of Anderson-Fabry Disease
Current Gene Therapy, 2019 Antonino, Tuttolomondo +2 more
openaire +2 more sources
MedComm, Volume 6, Issue 10, October 2025.This review summarizes strategies to optimize lipid nanoparticles (LNPs) for improved targeting, endosomal escape, and safety. It highlights mRNA design, alternative delivery systems, and recent therapeutic advances across infectious diseases, cancer, and drug applications.
Xiaochi Li +7 more
wiley +1 more source
Kidneys in Anderson-Fabry Disease
Acta clinica Croatica, 2005 Anderson-Fabry disease is an X-linked recessive glycolipid storage disease caused by deficient activity of the lysosomal enzyme alpha-galactosidase A. Numerous mutations are responsible for development of the disease. Clinical manifestations include acroparesthesia from childhood, corneal dystrophy, angiokeratomas, hypohidrosis, hearing loss and, with ...
Bašić Jukić, Nikolina, Kes, Petar
openaire +1 more source
A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac Amyloidosis
MedComm, Volume 6, Issue 7, July 2025.The present study was designed to assess the efficacy and safety of a dose‐tailored BD regimen and a dose‐tailored DBD regimen in patients with LCCA at Mayo Stage III. Both the two regimens markedly increased survival rate and time in those patients and the dose‐tailored DBD regimen was superior to the dose‐tailored BD regimen in both efficacy and ...
Yun Ti +8 more
wiley +1 more source
Anderson-Fabry, the histrionic disease: from genetics to clinical management
Cardiogenetics, 2013 Anderson-Fabry disease (AFD) is an Xlinked lysosomal storage disorder of glycosphingolipid catabolism, due to deficiency or absence of a galactosidase A (α-gal A) enzyme. The disease may affect males and females, the latter with an average 10 years
Franco Cecchi +2 more
doaj +1 more source
Anderson-Fabry disease: Worthy to in-SPECT the nerves? [PDF]
Journal of Nuclear Cardiology, 2021 Massalha, Samia, Slart, Riemer H. J. A.
openaire +3 more sources